EVALUATION OF THE FIRST-LINE IMMUNOMODULATING THERAPY EFFICACY IN PATIENTS WITH RELAPSING-REMITTING AND SECONDARY-PROGRESSIVE TYPES OF MULTIPLE SCLEROSIS